
Caristo Diagnostics
Coronary-inflammation biomarker analysis from cardiac CT images.
United Kingdom / Science and engineering / Early stage
Funding Now

Specialist venture capital and company-building for UK science and engineering, from early research to commercial businesses.
01 / The firm
Longwall backs IP-protected ventures in advanced manufacturing, life sciences, medical technologies, defence, clean energy and adjacent fields. It leads at pre-seed or seed, including before a proven market, and supports companies through complex development cycles.
Longwall Venture Partners LLP, registered in England and Wales as OC362933, operates from Harwell. Its registered office is in Thame. Venture activity began in 2008; the LLP was incorporated in 2011.
Its four fund generations include Oxford Technology ECF, Longwall Ventures ECF, Longwall Ventures 3 ECF and Longwall 4.
Longwall currently states an initial investment of up to £1.5 million. The British Business Bank's May 27, 2026 Fund 4 announcement described £500,000-£2 million investments, £86.2 million raised and a £100 million target.
02 / Portfolio
Selected investments from Longwall's portfolio, followed by historical exits.
Tools for biological research, diagnostics and therapy development.

Coronary-inflammation biomarker analysis from cardiac CT images.

Light-controlled microdroplet technology for functional single-cell analysis and screening.

Molecular technologies for genomic biomarker testing, including Aspyre and Enspyre.

Phosphoproteomic analysis of cell signalling to support drug development and treatment research.

Automated microfluidic bioprocessing for cell and gene therapy development. Prototypes are for research and development, not clinical or therapeutic use.

Proprietary oncology biomarkers and digital-pathology analysis tools for cancer treatment decisions.

SonoTran ultrasound-driven delivery platform for solid-tumour therapies. Investigational use only, not approved for sale.
Chemical-process spectroscopy, methane sensing and photovoltaic materials.
Metal additive manufacturing, optical sensing and analytical instrumentation.

Electron-beam metal additive manufacturing using the NeuBeam process.

Distributed optical sensing hardware for acoustic and movement monitoring over fibre infrastructure.

Quadrupole two-dimensional mass spectrometry for improving analytical separation in QTOF instruments.
Ultrasonic aeroponics technology for controlled-environment agriculture.
Deployable antenna systems for spacecraft.

Spatially offset Raman spectroscopy for non-invasive chemical analysis through opaque barriers. Acquired by Agilent.

Normothermic machine perfusion systems for preserving donor organs outside the body. Acquired by Terumo.

Clinical-stage small-molecule iron chelation technology, including SP-420. Acquired by Pharmacosmos.

Gallium-nitride and gallium-arsenide microwave solid-state power amplifiers. Longwall marks its investment exited; the company describes TMD as a shareholder, not an outright acquirer.
Historical rotary-steerable directional-drilling technology. Longwall reports an exit to Schoeller-Bleckmann.
Big-data analytics software. Longwall lists its investment as exited.
03 / People

Managing Partner
Physical science and engineering investing. Co-founder.

Managing Partner
Life science and healthcare investing. Co-founder.

Co-founder Michael Penington (1958-2024) retired in 2023. He is remembered on Longwall's team page and is not a current contact.
04 / Connect
For general enquiries, use Longwall's published firm mailbox. The investment team biographies above describe each person's focus.